Cargando…

Behavioral and Accumbal Responses During an Affective Go/No-Go Task Predict Adherence to Injectable Naltrexone Treatment in Opioid Use Disorder

Adherence is a major factor in the effectiveness of the injectable extended-release naltrexone as a relapse prevention treatment in opioid use disorder. We examined the value of a variant of the Go/No-go paradigm in predicting extended-release naltrexone adherence in 27 detoxified opioid use disorde...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Zhenhao, Jagannathan, Kanchana, Wang, An-Li, Fairchild, Victoria P, Lynch, Kevin G, Suh, Jesse J, Childress, Anna Rose, Langleben, Daniel D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6403086/
https://www.ncbi.nlm.nih.gov/pubmed/30690502
http://dx.doi.org/10.1093/ijnp/pyz002
_version_ 1783400506064896000
author Shi, Zhenhao
Jagannathan, Kanchana
Wang, An-Li
Fairchild, Victoria P
Lynch, Kevin G
Suh, Jesse J
Childress, Anna Rose
Langleben, Daniel D
author_facet Shi, Zhenhao
Jagannathan, Kanchana
Wang, An-Li
Fairchild, Victoria P
Lynch, Kevin G
Suh, Jesse J
Childress, Anna Rose
Langleben, Daniel D
author_sort Shi, Zhenhao
collection PubMed
description Adherence is a major factor in the effectiveness of the injectable extended-release naltrexone as a relapse prevention treatment in opioid use disorder. We examined the value of a variant of the Go/No-go paradigm in predicting extended-release naltrexone adherence in 27 detoxified opioid use disorder patients who were offered up to 3 monthly extended-release naltrexone injections. Before extended-release naltrexone, participants performed a Go/No-go task that comprised positively valenced Go trials and negatively valenced No-go trials during a functional magnetic resonance imaging scan. Errors of commission and neural responses to the No-go vs Go trials were independent variables. Adherence, operationalized as the completion of all 3 extended-release naltrexone injections, was the outcome variable. Fewer errors of commission and greater left accumbal response during the No-go vs Go trials predicted better adherence. These findings support the clinical potential of the behavioral and neurophysiological correlates of response inhibition in the prediction of extended-release naltrexone treatment outcomes in opioid use disorder.
format Online
Article
Text
id pubmed-6403086
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-64030862019-03-12 Behavioral and Accumbal Responses During an Affective Go/No-Go Task Predict Adherence to Injectable Naltrexone Treatment in Opioid Use Disorder Shi, Zhenhao Jagannathan, Kanchana Wang, An-Li Fairchild, Victoria P Lynch, Kevin G Suh, Jesse J Childress, Anna Rose Langleben, Daniel D Int J Neuropsychopharmacol Brief Report Adherence is a major factor in the effectiveness of the injectable extended-release naltrexone as a relapse prevention treatment in opioid use disorder. We examined the value of a variant of the Go/No-go paradigm in predicting extended-release naltrexone adherence in 27 detoxified opioid use disorder patients who were offered up to 3 monthly extended-release naltrexone injections. Before extended-release naltrexone, participants performed a Go/No-go task that comprised positively valenced Go trials and negatively valenced No-go trials during a functional magnetic resonance imaging scan. Errors of commission and neural responses to the No-go vs Go trials were independent variables. Adherence, operationalized as the completion of all 3 extended-release naltrexone injections, was the outcome variable. Fewer errors of commission and greater left accumbal response during the No-go vs Go trials predicted better adherence. These findings support the clinical potential of the behavioral and neurophysiological correlates of response inhibition in the prediction of extended-release naltrexone treatment outcomes in opioid use disorder. Oxford University Press 2019-01-23 /pmc/articles/PMC6403086/ /pubmed/30690502 http://dx.doi.org/10.1093/ijnp/pyz002 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of CINP. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Brief Report
Shi, Zhenhao
Jagannathan, Kanchana
Wang, An-Li
Fairchild, Victoria P
Lynch, Kevin G
Suh, Jesse J
Childress, Anna Rose
Langleben, Daniel D
Behavioral and Accumbal Responses During an Affective Go/No-Go Task Predict Adherence to Injectable Naltrexone Treatment in Opioid Use Disorder
title Behavioral and Accumbal Responses During an Affective Go/No-Go Task Predict Adherence to Injectable Naltrexone Treatment in Opioid Use Disorder
title_full Behavioral and Accumbal Responses During an Affective Go/No-Go Task Predict Adherence to Injectable Naltrexone Treatment in Opioid Use Disorder
title_fullStr Behavioral and Accumbal Responses During an Affective Go/No-Go Task Predict Adherence to Injectable Naltrexone Treatment in Opioid Use Disorder
title_full_unstemmed Behavioral and Accumbal Responses During an Affective Go/No-Go Task Predict Adherence to Injectable Naltrexone Treatment in Opioid Use Disorder
title_short Behavioral and Accumbal Responses During an Affective Go/No-Go Task Predict Adherence to Injectable Naltrexone Treatment in Opioid Use Disorder
title_sort behavioral and accumbal responses during an affective go/no-go task predict adherence to injectable naltrexone treatment in opioid use disorder
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6403086/
https://www.ncbi.nlm.nih.gov/pubmed/30690502
http://dx.doi.org/10.1093/ijnp/pyz002
work_keys_str_mv AT shizhenhao behavioralandaccumbalresponsesduringanaffectivegonogotaskpredictadherencetoinjectablenaltrexonetreatmentinopioidusedisorder
AT jagannathankanchana behavioralandaccumbalresponsesduringanaffectivegonogotaskpredictadherencetoinjectablenaltrexonetreatmentinopioidusedisorder
AT wanganli behavioralandaccumbalresponsesduringanaffectivegonogotaskpredictadherencetoinjectablenaltrexonetreatmentinopioidusedisorder
AT fairchildvictoriap behavioralandaccumbalresponsesduringanaffectivegonogotaskpredictadherencetoinjectablenaltrexonetreatmentinopioidusedisorder
AT lynchkeving behavioralandaccumbalresponsesduringanaffectivegonogotaskpredictadherencetoinjectablenaltrexonetreatmentinopioidusedisorder
AT suhjessej behavioralandaccumbalresponsesduringanaffectivegonogotaskpredictadherencetoinjectablenaltrexonetreatmentinopioidusedisorder
AT childressannarose behavioralandaccumbalresponsesduringanaffectivegonogotaskpredictadherencetoinjectablenaltrexonetreatmentinopioidusedisorder
AT langlebendanield behavioralandaccumbalresponsesduringanaffectivegonogotaskpredictadherencetoinjectablenaltrexonetreatmentinopioidusedisorder